Immunotherapy for Colorectal Cancer in India: MSI-High Tumours, Options and Cost

Quick answer: Immunotherapy helps a specific group of colorectal cancer patients: those whose tumours are MSI-high (microsatellite instability-high) or dMMR (mismatch repair deficient). In this group, checkpoint inhibitors can be an important treatment option. For the majority of colorectal cancers, which are microsatellite-stable (MSS), immunotherapy alone is not usually effective, and standard treatment such as surgery, chemotherapy and targeted therapy remains the foundation.

That one test result, MSI/MMR status, is the single most useful thing to know when asking about immunotherapy for colon or rectal cancer. This guide explains why, how the testing works and what to discuss with your oncologist.

What MSI-high and dMMR mean

Our cells have a repair system that fixes small copying errors in DNA. In some colorectal tumours this system is faulty (dMMR), so errors pile up and the tumour looks very “foreign” to the immune system. That makes it more likely to respond when checkpoint inhibitors remove the immune system’s brakes. Only a minority of colorectal cancers have this feature, so testing is essential rather than assumed.

Immunotherapy options for colorectal cancer

  • Checkpoint inhibitors for MSI-H/dMMR disease: medicines such as pembrolizumab, and combinations such as nivolumab with ipilimumab, have been used in metastatic MSI-H/dMMR colorectal cancer. Availability and approved uses in India depend on the current CDSCO label, so confirm with your oncologist.
  • Microsatellite-stable (MSS) disease: checkpoint inhibitors alone have shown limited benefit. Doctors may discuss clinical trials or other approaches.
  • Personalised cell-based therapy: dendritic cell therapy is offered at Denvax as part of an individual plan alongside standard care. Your doctor will explain what the evidence does and does not show for your situation.

For an overview of the drugs in use, see our guide to immunotherapy drugs for cancer and the list of checkpoint inhibitors available in India.

How to find out if your tumour is MSI-high

Two common laboratory methods exist: immunohistochemistry (IHC) for the mismatch repair proteins, and a molecular MSI test. Both are run on the biopsy or surgical sample at a pathology laboratory. Ask your treating team whether MSI/MMR status is already in your pathology report. Denvax does not perform diagnostic tests, so bring the report with you; if it is missing, your oncologist can advise where to request it.

Who should ask about immunotherapy?

  • Patients with advanced or metastatic colorectal cancer who have not yet had MSI/MMR testing
  • Patients whose report already shows MSI-H or dMMR
  • Patients whose cancer has progressed after chemotherapy and who want to understand remaining options
  • Families seeking a second opinion on whether immunotherapy fits the stage and biology of the disease

Side effects and monitoring

Checkpoint inhibitors can cause immune-related side effects, including colitis (bowel inflammation), skin reactions, thyroid changes and liver inflammation. Because colorectal cancer patients may already have bowel symptoms, new or worsening diarrhoea should be reported right away. Regular blood tests and scans are part of the plan.

Cost of immunotherapy for colorectal cancer in India

Cost depends on the medicine, dose, number of cycles, hospital charges and supportive care. Because treatment may continue for months, it helps to ask for a cycle-by-cycle estimate up front. Our guides to colorectal cancer treatment cost in India and immunotherapy costs in India explain the main cost drivers, and this page lists financial assistance options.

Frequently asked questions

Does immunotherapy work for all colon cancer patients?

No. It works best in MSI-high or dMMR tumours. Most colorectal cancers are microsatellite-stable and are treated mainly with surgery, chemotherapy and targeted therapy.

What is the difference between MSI-H and dMMR?

They describe the same underlying problem measured two ways: dMMR means the repair proteins are missing on a tissue stain, and MSI-H means the DNA pattern shows instability. Doctors usually treat them as equivalent for treatment decisions.

Can rectal cancer be treated with immunotherapy?

Immunotherapy is being studied in dMMR rectal cancer, but plans must be individualised and made with a multidisciplinary team. Ask your oncologist whether your case fits an approved use or a trial.

Is immunotherapy given with chemotherapy for colorectal cancer?

In MSI-H disease it is often used on its own, while in other settings it may be combined or sequenced differently. The plan depends on your stage, biomarkers and earlier treatment.

Should I get my MSI test done again?

Usually one reliable result is enough. If the first report is unclear or from a different sample type, your oncologist may advise repeating it.

Book a consultation with a Denvax oncologist to review your pathology report and discuss whether immunotherapy fits your colorectal cancer. निःशुल्क परामर्श बुक करें।

Medical review: [Reviewer name and qualifications to be added before publishing]. This article is for information and does not replace advice from your oncologist. Results may vary. Consult your oncologist.

Denvax Clinic

Denvax Clinic

You May Also Like

Denvax Clinic: India’s Leading Cancer Centre for Immunotherapy